Net sales grew 16% in Q2 2026, driven by organic growth and acquisitions, with adjusted EBITA up 28%. All business areas contributed to strong results, and recent acquisitions like Biopsafe and XGX Pharma are expected to further boost growth and margins.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.